澳大利亚脑膜炎球菌监测：报告期为2024年10月1日至12月31日。

IF 1.6 Q3 Medicine

Communicable diseases intelligence (2018) Pub Date : 2025-07-30 DOI:10.33321/cdi.2025.49.039

Monica M Lahra, Tiffany R Hogan

{"title":"澳大利亚脑膜炎球菌监测：报告期为2024年10月1日至12月31日。","authors":"Monica M Lahra, Tiffany R Hogan","doi":"10.33321/cdi.2025.49.039","DOIUrl":null,"url":null,"abstract":"Abstract: Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"49 ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Meningococcal Surveillance Australia: Reporting period 1 October to 31 December 2024.\",\"authors\":\"Monica M Lahra, Tiffany R Hogan\",\"doi\":\"10.33321/cdi.2025.49.039\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract: Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.\",\"PeriodicalId\":36867,\"journal\":{\"name\":\"Communicable diseases intelligence (2018)\",\"volume\":\"49 \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Communicable diseases intelligence (2018)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33321/cdi.2025.49.039\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Communicable diseases intelligence (2018)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33321/cdi.2025.49.039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

摘要：季度报告中的数据仅限于按辖区和血清组描述IMD病例数，并在2024年扩大到包括头孢曲松、青霉素、环丙沙星和利福平的抗微生物药物耐药性数据。AMSP年度报告中载有对每个历年实验室确认的IMD的全面分析。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Meningococcal Surveillance Australia: Reporting period 1 October to 31 December 2024.

Abstract: Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Communicable diseases intelligence (2018) Medicine-Medicine (all)

CiteScore

1.90

自引率

0.00%

发文量